IRS4
Basic information
Region (hg38): X:108719946-108736563
Links
Phenotypes
GenCC
Source:
- hypothyroidism, congenital, nongoitrous, 9 (Limited), mode of inheritance: XL
- hypothyroidism, congenital, nongoitrous, 9 (Strong), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hypothyroidism, congenital, nongoitrous, 9 | XL | Endocrine | The condition can manifest with early clinical signs, of hypothyroidism, and treatment with thyroid hormone replacement has been reported | Endocrine | 30061370 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IRS4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 9 | |||||
missense | 60 | 72 | ||||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 3 | 61 | 14 | 7 |
Variants in IRS4
This is a list of pathogenic ClinVar variants found in the IRS4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-108732576-G-T | Benign (Dec 31, 2019) | |||
X-108732617-A-C | Uncertain significance (Jan 08, 2022) | |||
X-108732657-C-A | not specified | Benign (Dec 31, 2019) | ||
X-108732669-G-T | not specified | Uncertain significance (Aug 17, 2022) | ||
X-108732693-G-C | not specified | Uncertain significance (Sep 26, 2023) | ||
X-108732721-A-C | Likely benign (Dec 01, 2022) | |||
X-108732755-G-A | not specified | Uncertain significance (Jun 29, 2023) | ||
X-108732809-T-C | not specified | Uncertain significance (Dec 17, 2023) | ||
X-108732811-G-T | Likely benign (Mar 01, 2023) | |||
X-108732828-C-T | not specified | Uncertain significance (Jun 29, 2023) | ||
X-108732873-C-T | Benign (Dec 31, 2019) | |||
X-108732928-C-A | Likely benign (Apr 01, 2022) | |||
X-108733023-G-C | not specified | Uncertain significance (Jul 14, 2023) | ||
X-108733045-G-C | Likely benign (Jan 01, 2023) | |||
X-108733130-G-A | Hypothyroidism, congenital, nongoitrous, 9 | Uncertain significance (Feb 28, 2020) | ||
X-108733163-G-T | not specified | Uncertain significance (Mar 15, 2024) | ||
X-108733179-TACAGC-T | Hypothyroidism, congenital, nongoitrous, 9 | Pathogenic (Sep 26, 2019) | ||
X-108733240-G-A | Benign (Dec 31, 2019) | |||
X-108733293-C-A | Likely pathogenic (Jun 12, 2021) | |||
X-108733295-A-G | not specified | Uncertain significance (Apr 16, 2024) | ||
X-108733305-C-T | not specified | Uncertain significance (Jun 13, 2023) | ||
X-108733320-C-A | IRS4-related disorder | Likely benign (Oct 26, 2020) | ||
X-108733344-G-A | not specified | Uncertain significance (Jan 11, 2023) | ||
X-108733461-C-T | not specified | Uncertain significance (Apr 18, 2023) | ||
X-108733493-G-A | Likely benign (Nov 01, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IRS4 | protein_coding | protein_coding | ENST00000372129 | 1 | 3940 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.578 | 0.422 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.0893 | 485 | 491 | 0.989 | 0.0000351 | 8088 |
Missense in Polyphen | 66 | 98.241 | 0.67182 | 1618 | ||
Synonymous | -3.56 | 262 | 198 | 1.32 | 0.0000146 | 2738 |
Loss of Function | 3.64 | 5 | 24.4 | 0.205 | 0.00000190 | 429 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as an interface between multiple growth factor receptors possessing tyrosine kinase activity, such as insulin receptor, IGF1R and FGFR1, and a complex network of intracellular signaling molecules containing SH2 domains. Involved in the IGF1R mitogenic signaling pathway. Promotes the AKT1 signaling pathway and BAD phosphorylation during insulin stimulation without activation of RPS6KB1 or the inhibition of apoptosis. Interaction with GRB2 enhances insulin-stimulated mitogen-activated protein kinase activity. May be involved in nonreceptor tyrosine kinase signaling in myoblasts. Plays a pivotal role in the proliferation/differentiation of hepatoblastoma cell through EPHB2 activation upon IGF1 stimulation. May play a role in the signal transduction in response to insulin and to a lesser extent in response to IL4 and GH on mitogenesis. Plays a role in growth, reproduction and glucose homeostasis. May act as negative regulators of the IGF1 signaling pathway by suppressing the function of IRS1 and IRS2. {ECO:0000269|PubMed:10531310, ECO:0000269|PubMed:10594015, ECO:0000269|PubMed:12639902, ECO:0000269|PubMed:17408801, ECO:0000269|PubMed:9553137}.;
- Pathway
- Regulation of lipolysis in adipocytes - Homo sapiens (human);Adipocytokine signaling pathway - Homo sapiens (human);Type II diabetes mellitus - Homo sapiens (human);Longevity regulating pathway - multiple species - Homo sapiens (human);Autophagy - animal - Homo sapiens (human);FoxO signaling pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Longevity regulating pathway - Homo sapiens (human);cGMP-PKG signaling pathway - Homo sapiens (human);Insulin signaling pathway - Homo sapiens (human);EGF-Core;IGF-Core;Adipogenesis;Angiopoietin Like Protein 8 Regulatory Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Leptin Insulin Overlap;Insulin Signaling;Signal Transduction;insulin Mam;Leptin;IRS-related events triggered by IGF1R;IGF1R signaling cascade;Signaling by Receptor Tyrosine Kinases;Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R);insulin
(Consensus)
Recessive Scores
- pRec
- 0.209
Intolerance Scores
- loftool
- 0.163
- rvis_EVS
- 0.54
- rvis_percentile_EVS
- 81.07
Haploinsufficiency Scores
- pHI
- 0.0550
- hipred
- Y
- hipred_score
- 0.597
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.914
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Irs4
- Phenotype
- reproductive system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- signal transduction;insulin receptor signaling pathway;positive regulation of signal transduction
- Cellular component
- cytosol;plasma membrane
- Molecular function
- SH3/SH2 adaptor activity;insulin receptor binding;protein binding;phosphatidylinositol 3-kinase binding